We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Simplified Antibiotic Therapy for Sepsis in Young Infants (SATT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01027429
Recruitment Status : Completed
First Posted : December 8, 2009
Last Update Posted : June 29, 2015
Sponsor:
Collaborators:
Save the Children
World Health Organization
London School of Hygiene and Tropical Medicine
Emory University
Information provided by (Responsible Party):
Anita Kaniz Mehdi Zaidi, Aga Khan University

Brief Summary:
This trial evaluates primary care clinic-based simplified antibiotic therapy options for young infants, 0-59 days old in high neonatal mortality settings in peri-urban Karachi where hospital referral is frequently refused by families.

Condition or disease Intervention/treatment Phase
Neonatal Sepsis Sepsis Infection Drug: procaine penicillin and gentamicin Drug: amoxicillin and gentamicin Drug: procaine penicillin, gentamicin, amoxicillin Phase 3

Detailed Description:

Primary Objective

To evaluate if out-patient (clinic-based) therapy of young infants with possible serious bacterial infection with 7 days of intramuscular procaine penicillin and gentamicin (reference therapy) is equivalent to:

  • (1) injectable gentamicin once daily and oral amoxicillin twice daily for seven days;
  • (2) injectable penicillin and gentamicin once daily for two days followed by oral amoxicillin twice daily for five days; and

Hypothesis

The proportion of babies who fail therapy at (or before 7) days will be 10% in each group. A 5% or less difference in failure rates will be considered equivalent.

Study Design

This will be a randomized, three arm, open-label equivalence trial among young infants, 0-59 days of age who are diagnosed as having possible serious bacterial infection in one of the Karachi field clinics, and whose families refuse facilitated hospital referral, and the infants meet other specified inclusion criteria.

Eligible young infants will be recruited from among those referred to the clinics by trained community health workers as having clinical signs predictive of possible serious illness during regular home visits in the surveillance area, or those presenting directly to the clinics from the areas under pregnancy and newborn surveillance. A diagnosis of possible sepsis will be made by clinicians if specified clinical criteria are met.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 2543 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Simplified Antibiotic Regimens for the Management of Sepsis in Young Infants in First-level Facilities: Randomized Controlled Trial
Study Start Date : December 2009
Actual Primary Completion Date : December 2013
Actual Study Completion Date : December 2013


Arm Intervention/treatment
Active Comparator: procaine penicillin and gentamicin
Procaine penicillin, 50,000 IU/kg by intramuscular injection plus gentamicin, 5 mg/kg intramuscular injection, both given once daily for 7 days
Drug: procaine penicillin and gentamicin
procaine penicillin 50,000 units/kg by intramuscular injection once daily for 7 days; gentamicin, 5 mg/kg once daily by intramuscular injection for 7 days

Drug: procaine penicillin, gentamicin, amoxicillin
procaine penicillin, 50,000 IU/kg once daily intramuscular injection plus gentamicin 5 mg/kg once daily intramuscular injection for 2 days, followed by 5 days of oral amoxicillin, 80-90 mg/kg divided in two doses.

Experimental: Amoxicillin and gentamicin
Oral amoxicillin (80-90 mg/kg) divided twice daily and intramuscular gentamicin, 5 mg/kg once daily, both given for 7 days
Drug: amoxicillin and gentamicin
oral amoxicillin 80-90 mg/kg divided in two doses for 7 days intramuscular gentamicin, 5 mg/kg once daily for 7 days

Drug: procaine penicillin, gentamicin, amoxicillin
procaine penicillin, 50,000 IU/kg once daily intramuscular injection plus gentamicin 5 mg/kg once daily intramuscular injection for 2 days, followed by 5 days of oral amoxicillin, 80-90 mg/kg divided in two doses.

Experimental: procaine penicillin, gentamicin, and amoxicillin
procaine penicillin, 50,000 IU/kg once daily intramuscular injection plus gentamicin 5 mg/kg once daily intramuscular injection for 2 days, followed by 5 days of oral amoxicillin, 80-90 mg/kg divided in two doses.
Drug: procaine penicillin, gentamicin, amoxicillin
procaine penicillin, 50,000 IU/kg once daily intramuscular injection plus gentamicin 5 mg/kg once daily intramuscular injection for 2 days, followed by 5 days of oral amoxicillin, 80-90 mg/kg divided in two doses.




Primary Outcome Measures :
  1. Treatment failure [ Time Frame: within 7 days of enrolment ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   up to 59 Days   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Inclusion Criteria

    • Infants 0-59 days old who are residents of catchment population of the study hospitals or clinics
    • One or more of the following five signs: severe chest in-drawing, axillary temperature >38.0C or <35.50 C, movement only when stimulated, and history of feeding problems (confirmed by poor suck on feeding assessment)
    • Family refuses recommended hospitalization or hospitalization otherwise not feasible
    • Informed consent by a legal guardian.
  • Exclusion Criteria:

Very severe infection/disease characterized by presence of any of the following signs (unconscious, convulsions, unable to feed, apnea, unable to cry, cyanosis, bulging fontanel, prolonged capillary refill, major congenital malformations, major bleeding, surgical conditions needing hospital referral, persistent vomiting defined as vomiting following three attempts to feed the baby within ½ hour)

  • Very low birth weight: weight <1500
  • Hospitalization for illness in the last two weeks
  • Previous inclusion in the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01027429


Locations
Layout table for location information
Pakistan
Ali Akber Shah Goth
Karachi, Sindh, Pakistan, 74800
Sponsors and Collaborators
Aga Khan University
Save the Children
World Health Organization
London School of Hygiene and Tropical Medicine
Emory University
Investigators
Layout table for investigator information
Study Director: Shiyam S Sunder, MBBS The Aga Khan University
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Anita Kaniz Mehdi Zaidi, Professor and Chair, Department of Paediatrics and Child Health, Aga Khan University
ClinicalTrials.gov Identifier: NCT01027429    
Other Study ID Numbers: SC134GL50124
First Posted: December 8, 2009    Key Record Dates
Last Update Posted: June 29, 2015
Last Verified: June 2015
Keywords provided by Anita Kaniz Mehdi Zaidi, Aga Khan University:
infant
newborn
sepsis
infection
community
Additional relevant MeSH terms:
Layout table for MeSH terms
Sepsis
Toxemia
Neonatal Sepsis
Infections
Systemic Inflammatory Response Syndrome
Inflammation
Pathologic Processes
Infant, Newborn, Diseases
Amoxicillin
Gentamicins
Penicillins
Penicillin G Procaine
Penicillin G
Penicillin G Benzathine
Procaine
Anti-Bacterial Agents
Anti-Infective Agents
Protein Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anesthetics, Local
Anesthetics
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents